[New drug approval: Adjuvant Pembrolizumab in clear-cell renal-cell carcinoma at high risk for recurrence after nephrectomy].Maxime Brunet, Gabriel G MaloufBulletin du cancer(2022)引用 0|浏览0暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要